| [1] |
Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a vising prostate-specific antigen level. Semin Oncol, 2003, 30(5): 616-634. doi: 10.1016/S0093-7754(03)00359-2
|
| [2] |
Scher B, Seitz M. PET/CT imaging of recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 2008, 35(1): 5-8. doi: 10.1007/s00259-007-0633-9
|
| [3] |
Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int, 2003, 70(4): 311-315. doi: 10.1159/000070141
|
| [4] |
Jorge RZ, Macarena R, Anibal RM, et al. Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level < 5ng/ml. Actas Urol Esp, 2009, 33(8): 844-852. doi: 10.1016/S0210-4806(09)72870-0
|
| [5] |
Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer, 2003, 39(11): 1525-1534. doi: 10.1016/S0959-8049(03)00374-5
|
| [6] |
Jadvar H, Xiankui L, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging, 2005, 4(2): 91-97.
|
| [7] |
Nakamoto Y, Osman M, Wahl RL. Prevalence and pattems of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med, 2003, 28(4): 302-307.
|